Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer (PFE) is running a Phase 2 study titled “AN ...

Vonoprazan (Voquezna) was noninferior to lansoprazole (Prevacid) for healing patients with erosive esophagitis, and was superior for maintaining healing, a randomized trial showed. In a modified ...

DelveInsight's, “Erosive Esophagitis Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Erosive Esophagitis pipeline landscape. It covers the ...

Please provide your email address to receive an email when new articles are posted on . A: This 52-year-old man with presumed gastroesophageal reflux disease, erosive esophagitis grade D, is referred ...

Background: Evidence regarding the association between alcohol consumption and the gastro-esophageal reflux disease (GERD) spectrum has been conflicting. We examined the association between alcohol ...

Vonoprazan is an oral small molecule potassium-competitive acid blocker. The Food and Drug Administration (FDA) has accepted for review the New Drug Application for vonoprazan as a treatment for the ...

throat The application is supported by data from the pivotal phase 3 PHALCON-EE trial which compared the efficacy and safety of vonoprazan to lansoprazole in patients with erosive esophagitis. The New ...

The report provides a detailed analysis of the current erosive esophagitis marketed drugs and late-stage pipeline drugs. BROOKLYN, NY, UNITED STATES, July 11, 2025 /EINPresswire / -- According to the ...

The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 ...

Los Angeles, CA – New clinical data demonstrated, for the first time in a prospective study, a direct relationship between controlling gastric (or stomach) acid and healing erosive esophagitis caused ...